[Beijing Direct News Network June 19] (Economic Daily)On June 12, Zhejiang Drug Administration issued the first batch of inspection notice of Zhejiang drug quality spot check in 2020. After the spot check by Zhejiang drug administration, 48 batches of drugs were found to be unqualified, involving Tianma (Anhui) State Pharmaceutical Technology Co., Ltd., Zhejiang Kangenbei Pharmaceutical Co., Ltd. and other companies.

According to the announcement, the non-conforming items of the 48 batches of non-conforming drugs involve properties, inspection, content determination, extract, etc. According to statistics, there are 27 batches of unqualified drugs, and 3 batches of unqualified drugs. For example, through the inspection of Zhoushan food and drug inspection and testing institute, the character of zhiyuanzhi (batch number: 190101) which is marked as produced by Tianma (Anhui) Guoyao Technology Co., Ltd. does not meet the requirements; through the inspection of Quzhou food and drug inspection and Research Institute, the extract of Qinpi (batch number: 141201) which is marked as produced by Zhejiang Kangenbei Pharmaceutical Co., Ltd. does not meet the requirements.

It is worth noting that the re inspection of Kudiezi Injection (18120203) produced by the label manufacturer for Shenyang Shuangding Pharmaceutical Co., Ltd. and fabianxia (18122101) produced by the label manufacturer for Anhui Xiehe pharmaceutical Yinpian Co., Ltd. meet the requirements.

According to Zhejiang drug administration, this announcement is the release of information on the inspection results of unqualified drugs, and the results of inspection and disposal (such as the situation that the manufacturer denies to be the manufacturer) will be separately released by the inspection and disposal department.